JP2021113191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021113191A5 JP2021113191A5 JP2021044152A JP2021044152A JP2021113191A5 JP 2021113191 A5 JP2021113191 A5 JP 2021113191A5 JP 2021044152 A JP2021044152 A JP 2021044152A JP 2021044152 A JP2021044152 A JP 2021044152A JP 2021113191 A5 JP2021113191 A5 JP 2021113191A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- antibody
- allylen
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 230000027455 binding Effects 0.000 claims 14
- 238000009739 binding Methods 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 11
- 125000005647 linker group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 125000000732 arylene group Chemical group 0.000 claims 5
- 125000005549 heteroarylene group Chemical group 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000021615 conjugation Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108060008539 Transglutaminase Proteins 0.000 claims 2
- 229940125644 antibody drug Drugs 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 102000003601 transglutaminase Human genes 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139044P | 2015-03-27 | 2015-03-27 | |
| US62/139,044 | 2015-03-27 | ||
| US201562252239P | 2015-11-06 | 2015-11-06 | |
| US62/252,239 | 2015-11-06 | ||
| JP2017550548A JP6948950B2 (ja) | 2015-03-27 | 2016-03-25 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550548A Division JP6948950B2 (ja) | 2015-03-27 | 2016-03-25 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021113191A JP2021113191A (ja) | 2021-08-05 |
| JP2021113191A5 true JP2021113191A5 (enExample) | 2022-02-01 |
Family
ID=55650789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550548A Active JP6948950B2 (ja) | 2015-03-27 | 2016-03-25 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
| JP2021044152A Withdrawn JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550548A Active JP6948950B2 (ja) | 2015-03-27 | 2016-03-25 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160375147A1 (enExample) |
| EP (1) | EP3273998B1 (enExample) |
| JP (2) | JP6948950B2 (enExample) |
| KR (2) | KR20240142591A (enExample) |
| CN (2) | CN107995912A (enExample) |
| AU (1) | AU2016243527B2 (enExample) |
| BR (1) | BR112017020149A8 (enExample) |
| CA (1) | CA2978340C (enExample) |
| CL (1) | CL2017002422A1 (enExample) |
| CO (1) | CO2017010890A2 (enExample) |
| EA (1) | EA034950B1 (enExample) |
| IL (1) | IL254267B (enExample) |
| MX (2) | MX386328B (enExample) |
| PH (1) | PH12017501780A1 (enExample) |
| SG (1) | SG11201707148PA (enExample) |
| WO (1) | WO2016160615A1 (enExample) |
| ZA (1) | ZA201706040B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA38496B2 (fr) | 2013-03-15 | 2021-01-29 | Regeneron Pharma | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques |
| WO2015031396A1 (en) | 2013-08-26 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| KR20240142591A (ko) * | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| WO2016205738A2 (en) | 2015-06-19 | 2016-12-22 | Cytrx Corporation | Delivery systems for controlled drug release |
| EP3722318A1 (en) | 2015-07-06 | 2020-10-14 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| IL265309B2 (en) | 2016-09-23 | 2024-04-01 | Regeneron Pharma | Bispecific anti-muc16 antibodies and anti-muc16 antibodies for use in treating cancer |
| CN110088138B (zh) | 2016-09-23 | 2023-08-25 | 瑞泽恩制药公司 | 抗steap2抗体、抗体药物偶联物和结合steap2和cd3的双特异性抗原结合分子以及其用途 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CA3044534A1 (en) | 2016-11-29 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| WO2018213077A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| EP3635009A1 (en) | 2017-06-07 | 2020-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| IL313068A (en) | 2017-11-07 | 2024-07-01 | Regeneron Pharma | Hydrophilic linkers for antibody drug conjugates |
| MX2020005472A (es) * | 2017-11-30 | 2020-11-11 | Centurion Biopharma Corp | Sistemas de administración de fármacos a base de maitansinoide. |
| MX2020011487A (es) | 2018-04-30 | 2020-12-07 | Regeneron Pharma | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. |
| CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| CN112638426B (zh) * | 2018-09-21 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
| JP2022523360A (ja) | 2019-02-21 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| CN114945369A (zh) | 2019-11-15 | 2022-08-26 | 思进公司 | 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法 |
| CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
| US11958910B2 (en) | 2020-02-28 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind HER2, and methods of use thereof |
| EP4135775A1 (en) | 2020-04-16 | 2023-02-22 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
| AU2021366691B2 (en) | 2020-10-22 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
| KR20230107261A (ko) | 2020-11-10 | 2023-07-14 | 리제너론 파마슈티칼스 인코포레이티드 | 셀레늄 항체 접합물 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| WO2005010151A2 (en) | 2003-06-27 | 2005-02-03 | Abgenix, Inc | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| WO2006062779A2 (en) | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
| PT2135881E (pt) | 2005-06-20 | 2011-12-21 | Genentech Inc | Anticorpos que se ligam ao antigénio tat10772 associado a tumor para o diagnóstico e tratamento de tumor |
| BRPI0612529A2 (pt) | 2005-06-20 | 2010-11-23 | Psma Dev Company Llc | conjugados de anticorpo-medicamento de psma |
| AU2006280146B2 (en) | 2005-08-09 | 2012-06-28 | Immunogen, Inc. | Method of acylating maytansinol with chiral amino acids |
| PT1977252E (pt) | 2005-12-22 | 2013-01-28 | Baxter Int | Teste de activação de monócitos melhorado mais capaz de detectar contaminantes pirogénicos sem serem endotoxinas em produtos médicos |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| EP2845866B1 (en) | 2006-10-27 | 2017-05-03 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| CN101687037B (zh) | 2007-05-08 | 2013-07-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗muc16抗体和抗体药物偶联物 |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| CA2990929C (en) | 2008-03-18 | 2022-04-12 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| CA2770617C (en) | 2009-08-10 | 2018-02-20 | Mark Smith | Reversible covalent linkage of functional molecules |
| AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| KR20120080611A (ko) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| NZ602241A (en) | 2010-04-15 | 2015-03-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| JP6146913B2 (ja) | 2010-08-02 | 2017-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｖｌドメインを含む結合タンパク質を作製するマウス |
| UA109150C2 (xx) | 2010-09-01 | 2015-07-27 | Аміди n-(тетразол-5-іл)- або n-(триазол-5-іл)арилкарбонової кислоти та їх застосування як гербіцидів | |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン， インコーポレイテッド | 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体 |
| JP2013542958A (ja) | 2010-11-03 | 2013-11-28 | イミュノジェン・インコーポレーテッド | アンサマイトシン誘導体を含む細胞傷害性剤 |
| US20160151505A1 (en) | 2011-05-16 | 2016-06-02 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| SG195183A1 (en) | 2011-05-27 | 2013-12-30 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EA201792652A3 (ru) | 2011-06-21 | 2018-09-28 | Иммуноджен, Инк. | Новые производные майтанзиноида с пептидным линкером и их конъюгаты |
| CN103987384A (zh) | 2011-10-14 | 2014-08-13 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| US20130224228A1 (en) | 2011-12-05 | 2013-08-29 | Igenica, Inc. | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| HK1204924A1 (en) | 2012-06-19 | 2015-12-11 | Polytherics Limited | Process for preparation of antibody conjugates and antibody conjugates |
| RS56953B1 (sr) | 2012-10-23 | 2018-05-31 | Synaffix Bv | Modifikovano antitelo, konjugat antitela i postupak za njihovu pripremu |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| US10131682B2 (en) * | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103333179B (zh) | 2012-12-21 | 2017-06-16 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| MA38496B2 (fr) | 2013-03-15 | 2021-01-29 | Regeneron Pharma | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques |
| CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| US20140363454A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| WO2015031396A1 (en) | 2013-08-26 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| WO2015081281A1 (en) | 2013-11-26 | 2015-06-04 | Segway Orthopaedics, Inc. | Surgical blade with viewing aperture |
| WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| EP3077402B1 (en) | 2013-12-02 | 2018-09-19 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| KR20240142591A (ko) * | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| CN110088138B (zh) | 2016-09-23 | 2023-08-25 | 瑞泽恩制药公司 | 抗steap2抗体、抗体药物偶联物和结合steap2和cd3的双特异性抗原结合分子以及其用途 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2016
- 2016-03-25 KR KR1020247030839A patent/KR20240142591A/ko active Pending
- 2016-03-25 CN CN201680030443.2A patent/CN107995912A/zh active Pending
- 2016-03-25 WO PCT/US2016/024343 patent/WO2016160615A1/en not_active Ceased
- 2016-03-25 KR KR1020177030678A patent/KR102708103B1/ko active Active
- 2016-03-25 CN CN202210829028.0A patent/CN115645543A/zh active Pending
- 2016-03-25 CA CA2978340A patent/CA2978340C/en active Active
- 2016-03-25 EP EP16714199.3A patent/EP3273998B1/en active Active
- 2016-03-25 BR BR112017020149A patent/BR112017020149A8/pt not_active Application Discontinuation
- 2016-03-25 US US15/081,759 patent/US20160375147A1/en not_active Abandoned
- 2016-03-25 MX MX2017012380A patent/MX386328B/es unknown
- 2016-03-25 JP JP2017550548A patent/JP6948950B2/ja active Active
- 2016-03-25 SG SG11201707148PA patent/SG11201707148PA/en unknown
- 2016-03-25 EA EA201700464A patent/EA034950B1/ru unknown
- 2016-03-25 AU AU2016243527A patent/AU2016243527B2/en active Active
-
2017
- 2017-09-01 IL IL254267A patent/IL254267B/en active IP Right Grant
- 2017-09-05 ZA ZA2017/06040A patent/ZA201706040B/en unknown
- 2017-09-26 CL CL2017002422A patent/CL2017002422A1/es unknown
- 2017-09-27 MX MX2021008101A patent/MX2021008101A/es unknown
- 2017-09-27 PH PH12017501780A patent/PH12017501780A1/en unknown
- 2017-10-26 CO CONC2017/0010890A patent/CO2017010890A2/es unknown
-
2019
- 2019-12-12 US US16/712,941 patent/US20200385402A1/en not_active Abandoned
-
2021
- 2021-03-17 JP JP2021044152A patent/JP2021113191A/ja not_active Withdrawn
- 2021-11-16 US US17/528,144 patent/US12297207B2/en active Active
-
2025
- 2025-03-28 US US19/093,440 patent/US20250223299A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021113191A5 (enExample) | ||
| JP2018516851A5 (enExample) | ||
| JP2019172710A5 (enExample) | ||
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JP6721572B2 (ja) | ジスルフィド含有タンパク質からコンジュゲートを作製するための方法 | |
| JP6966741B2 (ja) | 放射性標識薬剤 | |
| JP2021121590A5 (enExample) | ||
| RU2016139340A (ru) | Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой | |
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| JPWO2020031936A5 (enExample) | ||
| JPWO2022102695A5 (enExample) | ||
| JP2015526434A5 (enExample) | ||
| JP2017537893A5 (enExample) | ||
| WO2005077071A3 (en) | Therapeutic and diagnostic conjugates for use with multispecific antibodies | |
| RU2013128361A (ru) | Her2-связывающие белки, меченые комплексом 18f-фторида алюминия и nota | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| CN114917358A (zh) | 用于治疗癌症和炎症性疾病的偶联物和前药 | |
| JPWO2022102634A5 (enExample) | ||
| JPWO2019136487A5 (enExample) | ||
| WO2013081091A1 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
| CN119264413A (zh) | 聚乙二醇衍生物及其用途 | |
| JP2020509010A5 (enExample) | ||
| EP3727465A2 (en) | Transition metal-based functional moieties for preparing cell targeting conjugates | |
| JP7356677B2 (ja) | 複合体 | |
| JP2004524323A5 (enExample) |